MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017 · Journal of Clinical Oncology · 1,620 citations
https://doi.org/10.1200/jco.2017.73.7585
A
Antonio Llombart‐Cussac
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
694
Papers
16.2K
Citations
59
h-index
199
i10-index
Antonio Llombart‐Cussac is an academic researcher from Universidad Cardenal Herrera CEU. The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 59, co-authored 590 publications.
ORCID: 0000-0003-4515-8293Papers by this author
worksRelationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
2008 · Journal of Clinical Oncology · 463 citations
https://doi.org/10.1200/jco.2007.12.9437
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
2022 · Neuro-Oncology · 242 citations
https://doi.org/10.1093/neuonc/noac144
A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer
2007 · Journal of Clinical Oncology · 203 citations
https://doi.org/10.1200/jco.2006.09.6578
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
2003 · PubMed · 202 citations
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
2019 · The Lancet Oncology · 194 citations
https://doi.org/10.1016/s1470-2045(19)30786-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat